RapidAI (formerly iSchemaView)
About RapidAI (formerly iSchemaView)
RapidAI (formerly iSchemaView) is a global leader in AI-driven medical imaging and workflow solutions, primarily focused on cerebrovascular and neurovascular conditions. The company’s platform leverages artificial intelligence to analyze medical images, such as CT and MRI scans, providing rapid and accurate insights to physicians. This technology aids in the faster diagnosis and treatment decision-making for critical conditions like ischemic stroke, hemorrhagic stroke, aneurysm, and trauma.
For physicians, RapidAI’s solutions are designed to streamline clinical workflows and enhance care team collaboration. The platform integrates seamlessly with hospital Picture Archiving and Communication Systems (PACS) and offers mobile applications for anytime, anywhere access to critical patient images and results. This enables more efficient communication among stroke teams and radiologists, ultimately reducing time to treatment and improving patient outcomes. The company’s technology is clinically validated and has received FDA clearances for various applications, with its solutions utilized in over 2,500 hospitals across more than 100 countries.
Focus Areas
Business Intelligence
| Key Investors | Vista Credit Partners, Vista Equity Partners, Lennertz & Co., Cullom Capital, Listwin Ventures |
| Partnerships | Amazon Web Services (AWS), Alaska Stroke Coalition, Spectro Cloud, Ambra Health, Samsung Neurologica, Mobile Heartbeat, Halo Health, Pulsara, Siemens Healthineers, Saudi Arabia's Health Holdings |
| Acquisitions | EndoVantage |
| Technology | Rapid Enterprise™ Platform, Rapid Edge Cloud (hybrid infrastructure), Deep Clinical AI, AI Orchestrator, Cloud-native, Edge computing (Kubernetes), Mobile applications, Integration with PACS and EHR systems |
| FDA Clearances | 13+ cleared products (estimated) |
What Physicians Need to Know
RapidAI stands out for physicians by offering 'Deep Clinical AI' that goes beyond basic detection to provide real-time, patient-specific, and contextual insights, significantly reducing cognitive burden and manual work. Its clinically validated algorithms, backed by peer-reviewed outcomes and real-world evidence, enhance diagnostic accuracy and support faster, more confident treatment decisions. The platform's ability to extend the ischemic stroke treatment window up to 24 hours provides more time for informed decision-making, leading to better patient outcomes. Physicians benefit from improved care coordination through secure mobile, desktop, and workstation tools, enabling instant notifications and streamlined communication among multidisciplinary teams. The automated image processing and analysis, with high sensitivity and specificity for conditions like ICH and LVO, empower physicians to manage higher case volumes efficiently and combat burnout.
RapidAI's Enterprise Platform is designed for seamless integration within existing hospital ecosystems. It embeds AI directly into tools clinicians already use, such as PACS (Picture Archiving and Communication Systems), EHRs (Electronic Health Records), worklists, and reporting systems. The platform also supports the integration of curated third-party algorithms, extending coverage across various service lines. A notable integration is with Pulsara, which allows care teams to receive RapidAI results and access images within the Pulsara app, streamlining communication and workflow for stroke care.
What the Web Says
RapidAI (formerly iSchemaView) develops AI-driven imaging solutions primarily for stroke, trauma, and vascular conditions, assisting physicians in diagnosing and treating conditions like stroke and subdural hematomas by analyzing brain scans and expediting treatment decisions. The platform integrates into hospital systems via PACS and mobile apps, providing results within minutes. While the technology is praised for its speed and accuracy in stroke detection, employee reviews indicate a mixed experience, with some highlighting a toxic sales culture and high turnover in executive teams, while others appreciate the remote work flexibility and positive impact of the technology.
Overall: MixedStrengths
- AI-powered clinical decision support software helps physicians make faster and more accurate decisions, particularly in stroke, aneurysm, and pulmonary embolism care.
- Reduces time needed to generate perfusion maps and improves information sharing among clinical teams, supporting faster clinical decision-making.
- Platform is designed for speed, security, scalability, and flexibility, offering customization to meet specific hospital needs.
- Accurate detection of intracranial hemorrhage, LVO, and CT perfusion, with results in 1-2 minutes.
- Helps facilitate transfer of patients requiring more intervention.
- Offers flexibility for remote work and directly impacts patient lives.
Limitations
- Some employee reviews mention a toxic sales culture and micromanagement.
- Reports of a horrible executive team and high turnover, with some employees experiencing mental abuse.
- Mobile app can be glitchy, with issues logging in, incorrect site setup messages, and missed notifications.
- Impact on many important clinical outcomes, including patient harms, mortality, quality of life, and length of hospital stay, is uncertain due to limited evidence.
- Cost-effectiveness for stroke detection is currently unknown.
- Lack of transparency regarding the development methods of machine-learning models, raising concerns about representativeness of training data and potential for algorithmic bias.
Based on reviews from: Elion, Indeed.com, Rapidai.tech, NCBI Bookshelf, Slashdot, Zippia, Canadian Journal of Health Technologies, App Store, Reddit
Last updated: 2026-07-19
Videos
News, demos, and interviews about RapidAI (formerly iSchemaView).
Videos load interactively. If none appear, search YouTube for RapidAI (formerly iSchemaView) →
Press & Coverage
Frequently Asked Questions
Comparisons
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]